Drug Profile
Istiratumab companion diagnostic - Merrimack Pharmaceuticals
Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator Merrimack Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pancreatic cancer; Solid tumours
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(Diagnosis) in USA
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(Diagnosis) in France
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(Diagnosis) in USA